Literature DB >> 20507037

Research update and recent developments in the management of scoliosis in neurofibromatosis type 1.

Zhenyu Wang1, Yi Liu.   

Abstract

Neurofibromatosis type 1 (NF-1) is an autosomal dominant hereditary disease characterized by an abnormal proliferation of cells from the neural crest. Neurofibromatosis type 1 is often associated with orthopedic disorders, especially scoliosis, which is the most common skeletal manifestation of NF-1. The effects of treatment of scoliosis in NF-1 are less satisfactory than other scoliotic types due to the particular pathogenesis and clinical characteristics. Early diagnosis and treatment may be the best way to improve outcomes. This article summarizes the recent genetic and clinical developments of scoliosis in NF-1. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Year:  2010        PMID: 20507037     DOI: 10.3928/01477447-20100329-20

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

1.  Young stroke due to vascular anomaly from neurofibromatosis type 1.

Authors:  Vachagan Krishnaswami; James Gilmore; Djamil Vahidassr
Journal:  BMJ Case Rep       Date:  2012-09-21

2.  Case report of surgical treatment of scoliosis caused by neurofibroma located posterior mediastinum.

Authors:  Nozomu Motono; Masahito Kawaguchi; Norio Kawahara; Hidetaka Uramoto
Journal:  Int J Surg Case Rep       Date:  2018-11-01

3.  How to rectify the convex coronal imbalance in patients with unstable dystrophic scoliosis secondary to type I neurofibromatosis: experience from a case series.

Authors:  Saihu Mao; Song Li; Yanyu Ma; Ben-Long Shi; Zhen Liu; Ze-Zhang Zhu; Jun Qiao; Yong Qiu
Journal:  BMC Musculoskelet Disord       Date:  2022-04-20       Impact factor: 2.562

Review 4.  Pathological Features and Surgical Strategies of Cervical Deformity.

Authors:  Xiangyao Sun; Siyuan Sun; Chao Kong; Wei Wang; Tongtong Zhang; Junzhe Ding; Xiangyu Li; Shibao Lu
Journal:  Biomed Res Int       Date:  2020-05-12       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.